Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia

May 17, 2018, Rockefeller University Press
In the femur of a control mouse (left), AML cells (white arrowhead) have displaced most of the normal bone marrow cells (black arrowhead). But the situation is reversed upon treatment with antibodies targeting IL1RAP (right). Credit: Mitchell et al., 2018

Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers.

AML is driven by that differentiate abnormally and proliferate excessively, eventually displacing normal, healthy from the bone marrow. Leukemic stem are usually resistant to traditional chemotherapies, and so researchers are trying to develop new, more targeted approaches to eliminate these crucial cells.

One possible target is a protein called interleukin-1 receptor accessory protein (IL1RAP), which is often highly expressed on the surface of leukemic stem cells but largely absent from normal blood stem cells. But whether leukemic stem cells require IL1RAP to survive and proliferate—and therefore whether inhibiting IL1RAP could be a successful way to treat AML—is unclear.

A team of researchers led by Ulrich Steidl at the Albert Einstein College of Medicine found that antibodies, small hairpin RNAs, or genetic deletion targeting IL1RAP induce the death of AML cells, including leukemic stem cells, isolated from patients. The effects were seen in the absence of immune effector cells, indicating that AML cells intrinsically depend on IL1RAP. In contrast, antibodies targeting IL1RAP had no effect on the growth and survival of normal blood cells. Antibody treatment also inhibited the proliferation of AML cells in mice without causing any negative side effects.

As its name suggests, IL1RAP works in conjunction with the interleukin-1 receptor to promote an inflammatory signaling pathway that could play a key role in the development of AML. But Steidl and colleagues found that IL1RAP also enhances the activity of two other membrane receptor proteins, FLT3 and c-KIT, that are known to stimulate the proliferation of leukemic stem cells when activated by their ligands. IL1RAP antibodies inhibited the ability of these ligands to induce the proliferation of AML cells.

"Our findings show that IL1RAP can amplify multiple key pathways in AML, demonstrating a much broader role for this protein in disease pathogenesis than previously appreciated," Steidl explains.

Researchers are currently developing ways to prompt a patient's own immune cells to selectively recognize and kill IL1RAP-expressing cancer cells, but AML patients generally have defective immune systems. This new research suggests that directly targeting IL1RAP with antibodies or specific drug molecules could be even more effective at killing AML cells. The findings also suggest that IL1RAP-directed immunotherapies could be even more promising than currently assumed. Because AML cells functionally depend on IL1RAP, they cannot simply down-regulate the to escape immunotherapy and are therefore less likely to develop therapeutic resistance.

"Importantly, as IL1RAP is also overexpressed in the stem cells of chronic myeloid leukemia and high-risk myelodysplastic syndromes, there is significant therapeutic potential in further developing IL1RAP-directed targeting strategies," Steidl says.

Explore further: Researchers identify new gene linked to amyloid beta plaque buildup in Alzheimer's disease

More information: Mitchell et al., 2018. J. Exp. Med. jem.rupress.org/cgi/doi/10.1084/jem.20180147

Related Stories

Researchers identify new gene linked to amyloid beta plaque buildup in Alzheimer's disease

October 5, 2015
In a newly published study, a multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains ...

Novel drug shows promise against acute myeloid leukemia

April 11, 2018
In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute ...

Not just a stem cell marker

January 22, 2018
The protein CD34 is predominantly regarded as a marker of blood-forming stem cells but it helps with migration to the bone marrow too.

Inhibiting CDK6 prevents leukemic relapse

January 27, 2015
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at ...

Screening drugs to kill cancer cells in their safe spaces

October 31, 2016
Existing chemotherapy approaches treat cancer by targeting cells that are actively multiplying and have a high metabolic rate. However, cancer stem cells can escape this targeting, leading to chemotherapy-resistant cancer ...

Blocking key pathways is a way to defeat cancer stem cells

October 25, 2017
Scientists from the RIKEN Center for Integrative Medical Sciences in Japan and international collaborators have found that in humanized mice, a cocktail of drugs blocking certain key pathways is effective in eliminating acute ...

Recommended for you

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.